Correlation of eosinophilia with clinical response in patients with advanced carcinoma treated with low-dose recombinant interleukin-2 and mitomycin C (Q68026604)

From Wikidata

Jump to navigation Jump to search

scientific article published on 01 January 1992

Language	Label	Description	Also known as
English	Correlation of eosinophilia with clinical response in patients with advanced carcinoma treated with low-dose recombinant interleukin-2 and mitomycin C	scientific article published on 01 January 1992

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1511459%20AND%20SRC:MED&resulttype=core&format=json

20 September 2019

Correlation of eosinophilia with clinical response in patients with advanced carcinoma treated with low-dose recombinant interleukin-2 and mitomycin C (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1511459%20AND%20SRC:MED&resulttype=core&format=json

20 September 2019

author name string

S. Arinaga

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1511459

3 October 2022

N. Karimine

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1511459

3 October 2022

K. Takamuku

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1511459

3 October 2022

S. Nanbara

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1511459

3 October 2022

H. Inoue

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1511459

3 October 2022

R. Abe

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1511459

3 October 2022

D. Watanabe

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1511459

3 October 2022

H. Matsuoka

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1511459

3 October 2022

H. Ueo

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1511459

3 October 2022

T. Akiyoshi

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1511459

3 October 2022

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1511459

3 October 2022

publication date

1 January 1992

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1511459%20AND%20SRC:MED&resulttype=core&format=json

20 September 2019

Cancer Immunology, Immunotherapy

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1511459%20AND%20SRC:MED&resulttype=core&format=json

20 September 2019

35

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1511459%20AND%20SRC:MED&resulttype=core&format=json

20 September 2019

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1511459%20AND%20SRC:MED&resulttype=core&format=json

20 September 2019

246-250

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1511459%20AND%20SRC:MED&resulttype=core&format=json

20 September 2019

Cytokine gene expression during the generation of human lymphokine-activated killer cells: early induction of interleukin 1 beta by interleukin 2.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1511459

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Role of IL-5 in IL-2-induced eosinophilia. In vivo and in vitro expression of IL-5 mRNA by IL-2

1 reference

https://pubmed.ncbi.nlm.nih.gov/1511459

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activation of eosinophils in cancer patients treated with IL-2 and IL-2-generated lymphokine-activated killer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/1511459

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adoptive immunotherapy for stage IV renal cell carcinoma: a novel protocol utilizing periodate and interleukin-2-activated autologous leukocytes and continuous infusions of low-dose interleukin-2.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1511459

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumour inhibition by interleukin-2 at the tumour/host interface

1 reference

https://pubmed.ncbi.nlm.nih.gov/1511459

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Correlation between clinical response to interleukin 2 therapy and sustained production of tumor necrosis factor

1 reference

https://pubmed.ncbi.nlm.nih.gov/1511459

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hematologic effects of immunotherapy with lymphokine-activated killer cells and recombinant interleukin-2 in cancer patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1511459

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation

1 reference

https://pubmed.ncbi.nlm.nih.gov/1511459

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Local responses in primary and secondary human lung cancers. II. Clinical correlations

1 reference

https://pubmed.ncbi.nlm.nih.gov/1511459

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Induction of endogenous cytokine-mRNA in circulating peripheral blood mononuclear cells by IL-2 administration to cancer patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1511459

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Translation of interleukin 2 mRNA from human peripheral blood leukocytes in Xenopus oocytes

1 reference

https://pubmed.ncbi.nlm.nih.gov/1511459

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/1511459

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of high-dose intermittent interleukin-2 in metastatic renal cell carcinoma: a Southwest Oncology Group study

1 reference

https://pubmed.ncbi.nlm.nih.gov/1511459

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Augmentation of the generation of lymphokine-activated killer cells after a single dose of mitomycin C in cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/1511459

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Human interleukin-5 (IL-5) regulates the production of eosinophils in human bone marrow cultures: comparison and interaction with IL-1, IL-3, IL-6, and GMCSF

1 reference

https://pubmed.ncbi.nlm.nih.gov/1511459

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumour-associated eosinophilia: a review

1 reference

https://pubmed.ncbi.nlm.nih.gov/1511459

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma [corrected].

1 reference

https://pubmed.ncbi.nlm.nih.gov/1511459

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunomodulatory properties and toxicity of interleukin 2 in patients with cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/1511459

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recombinant human granulocyte-macrophage colony-stimulating factor stimulates in vitro mature human neutrophil and eosinophil function, surface receptor expression, and survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/1511459

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of recombinant interleukin 2 in combination with mitomycin C on advanced cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/1511459

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/1511459

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Human eosinophils have prolonged survival, enhanced functional properties, and become hypodense when exposed to human interleukin 3.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1511459

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recombinant human interleukin 5 is a selective activator of human eosinophil function

1 reference

https://pubmed.ncbi.nlm.nih.gov/1511459

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

https://pubmed.ncbi.nlm.nih.gov/1511459

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/1511459

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Eosinophilia and fluid retention in systemic administration of interleukin-2

1 reference

https://pubmed.ncbi.nlm.nih.gov/1511459

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Eosinophil infiltration of human colonic carcinomas as a prognostic indicator

1 reference

https://pubmed.ncbi.nlm.nih.gov/1511459

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunomodulatory effects of systemic low-dose recombinant interleukin-2 and lymphokine-activated killer cells in humans.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1511459

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/BF01789330

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1511459%20AND%20SRC:MED&resulttype=core&format=json

20 September 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1511459%20AND%20SRC:MED&resulttype=core&format=json

20 September 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q68026604&oldid=2218437392"